Dublin, April 22, 2024 (GLOBE NEWSWIRE) -- The "Uremic Pruritus - Pipeline Insight, 2024" drug pipelines has been added to ResearchAndMarkets.com's offering. The report provides comprehensive insights ...

In March 2017, Kissei Pharmaceutical and Maruishi Pharmaceutical entered into a collaboration deal for the development and sales/marketing of the kappa opioid receptor agonist "MR13A9" to treat Uremic ...

Please provide your email address to receive an email when new articles are posted on . An association was found between uremic pruritis and adverse long-term outcomes for patients on dialysis, ...

Trevi Therapeutics announced statistically significant results from its Phase 2/3 trial of Nalbuphine ER for the treatment of moderate to severe uremic pruritus. Uremic pruritus is a persistent and ...

Uremic pruritus is a debilitating symptom frequently encountered in individuals with chronic kidney disease (CKD), particularly those receiving haemodialysis. This condition, characterised by ...

Aside from kidney transplantation, no effective treatment exists for uremic pruritus. The capacity of κ-opioid stimulation to block µ-opioid-induced itching implies that the new κ-opioid receptor ...

WASHINGTON, DC — The intensity of itch experienced by patients on hemodialysis with uremic pruritus can be eased with 12 weeks of treatment with difelikefalin (Korsuva, Cara Therapeutics), results ...

"Uremic Pruritus Pipeline Insight"DelveInsight's,“Uremic Pruritus - Pipeline Insight, 2025” report provides comprehensive insights about 2+ companies and 2+ pipeline drugs in Uremic Pruritus pipeline ...

Chicago, IL - Persistent uremic pruritus is frequently underrecognized in the modern dialysis era, according to a national survey presented here [ 1, 2, 3]. Nephrologists also tend to underestimate ...

In March 2017, Kissei Pharmaceutical and Maruishi Pharmaceutical entered into a collaboration deal for the development and sales/marketing of the kappa opioid receptor agonist "MR13A9" to treat Uremic ...